NR4A1 and breast cancer: The phase II WJOG9917B NEWBEAT study evaluated the triple combination of PD-1 inhibitor nivolumab, bevacizumab, and paclitaxel in the first-line treatment for patients with TNBC (n = 18, 32%) or hormone receptor-positive breast cancer (n = 39, 68%) (32).